Odyssey Therapeutics (ODTX)

• Market cap: $1.01B
• 1 day: 1.64%
• 5 days: -4.36%
• 1 month: 19.65%
• 3 months: 21.16%
• 6 months: 28.32%
• Year to date: 28.32%
• 1 year: 28.32%
• 5 years: 28.32%
• 10 years: 28.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.